About this trial
VISION-2 is an international, multi-site, prospective observational cohort study of 20,000 patients undergoing noncardiac surgery. Continuous biometric data will be blindly collected for the first 30 postoperative days, in hospital and at home, using Vitaliti™. Following study enrollment and baseline data collection, follow up visits will occur in-hospital, at 30-days, and 1-year post-operatively.
VISION-2 has 3 primary objectives, among participants who underwent noncardiac surgery, the investigators will: 1) determine the pattern and frequency of physiological precursors (i.e., biophysical signals) to MINS, BIMS, sepsis, and infection without sepsis; 2) build prediction models from these biophysical signals and their extracted features through supervised machine learning, for the prediction and early detection of those complications; and 3) build a biobank for evaluation of novel biomarkers.
Eligibility criteria
Qualifiers
age ≥65 years;
underwent non-cardiac surgery with general, neuraxial, local, or regional anesthesia; and
expected length of hospital stay of 3 or more days
Disqualifiers
hearing aid(s) or cochlear implant(s) in left ear;
pacemaker/implantable cardioverter-defibrillator (ICD);
externally programmable cerebrospinal fluid shunt;
deep brain stimulator;
Trial design
Treatments tested in this trial
- Continuous vital signs measurement device
Treatment groups
Sponsors and collaborators
Hamilton Health Sciences Corporation
Lead sponsor
McMaster University
Collaborator
Canadian Institutes of Health Research (CIHR)
Collaborator
Population Health Research Institute
Collaborator